antibodies

December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
October 28, 2021

VUMC researchers a step closer to broad ebolavirus protection

By Bill Snyder
Seth Zost, PhD, has been honored for his research on COVID-19 and other life-threatening viral diseases.
October 28, 2021

Zost honored for research on COVID-19, other life-threatening viral diseases

Vanderbilt’s Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

By Bill Snyder
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

By Bill Snyder
August 24, 2021

Autoimmunity advance

Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.

By Leigh MacMillan
August 10, 2021

Shared antibodies may push COVID-19 variants: VUMC study

Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.
By Bill Snyder
March 4, 2021

Chikungunya antibody identified at VUMC moves forward

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
By Bill Snyder
October 13, 2020

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
By Bill Snyder
September 17, 2020

Study finds COVID-19 antibodies drop substantially in the weeks following infection

The antibody levels to SAR-CoV-2, the virus that causes COVID-19, substantially drop in the weeks following infection, according to a study led by Vanderbilt University Medical Center and the Centers for Disease Control and Prevention (CDC).
By Nancy Humphrey
August 20, 2020

Study identifies antibodies that block alphaviruses

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.
By Bill Snyder
July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
By Bill Snyder
May 14, 2020

Antibodies eye Pacific Island “fever”

Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
By Bill Snyder
1 2 3 4